MBL obtained manufacturing and marketing approval on September 14, 2022 for its new GLINE-SARS-CoV-2&FluA+B, a simple test kit that simultaneously detects both the SARS-CoV-2 antigen and influenza virus antigen in a single test cassette. Sales will begin on September 30.
This kit detects the SARS-CoV-2 antigen, influenza A virus antigen, and influenza B virus antigen in nasopharyngeal or nasal swab fluid using an immunochromatographic* method.
*Immunochromatography: A method to test for viral infection by dropping a sample into a kit. Since it uses capillary action, no machine is required for the test, and the test can be performed visually. It is a simple and rapid method that can determine the result within 15~20 minutes after specimen is dropped into the reaction cassette.
A single test cassette is used to test for influenza A and B viruses as well as novel coronaviruses.
The ability to perform both tests with a single specimen collection reduces the burden on patients at the time of sample collection, as well as the testing workload for healthcare professionals.
Contact details
-
- Missy Bindseil
-
JSR Life Sciences Company Inquiries
Director, Marketing & Communications - mbindseil@jsr-nahq.com
Related topics
Related news
MEBGEN™ BRAF 2 Kit Receives MHLW Approval as a Companion Diagnostic for Use with Patients with Thyroid Cancer
With this approval, the MEBGEN™ BRAF 2 Kit is expected to contribute to the timely personalized treatment for patients with radically unresectable thyroid cancer based on the presence or absence of...
Notice of Approval for First-Class Marketing License for Medical Devices
With the acquisition of the First-Class Marketing License for Medical Devices, MBL will be able to market highly controlled medical devices, including genetic testing systems using NGS.
Launch of a New Chemiluminescence Immunoassay Analyzer “iStar500”
The iStar is a highly automated mono-test analyzer based on CLIA technology. The compact & integrated design, combined with highly sensitive CLIA technology, makes it an ideal choice for emergency ...
MEBGEN™ BRAF 3 Kit Receives MHLW Approval and Insurance Coverage as a Tumor Agnostic Companion Diagnostic
With MHLW approval and insurance coverage, the MEBGEN™ BRAF 3 Kit is expected to support personalized medicine based on its ability to detect the presence or absence of BRAF gene mutations in rare ...
New Antibody Development for Use in Drug Delivery to Motor Nerves
MBL raised and delivered monoclonal antibodies for Jiksak Bioengineering, a startup company with proprietary technologies developed for new therapeutic innovation in motor neuron degenerative disea...